Cellular senescence, the state in which cells permanently stop dividing but refuse to die, is a well-established driver of aging and a wide range of age-related pathologies. Senescent cells progressively accumulate in the tissues of aging mice and primates, and genetic or pharmacological clearance of these cells has been shown to extend both healthspan and longevity in naturally aged mice. Beyond aging itself, senescence is implicated in hepatic steatosis, obesity-associated metabolic syndrome, type I and type II diabetes, atherosclerosis, Alzheimer’s disease, and Parkinson’s disease. Decades of evidence have also linked aging to a relaxation of heterochromatin, the tightly packed, transcriptionally silent form of chromatin, and this loosening allows L1 elements to escape repression. The research team led by Anke Geng and Ying Jiang set out to determine whether SIRT1, whose protein levels decline during senescence and aging, directly guards the L1 genome and thereby influences the senescence program.

The investigators began with a well-characterized GFP-based reporter assay in HeLa cells, which quantifies L1 retrotransposition efficiency by detecting when an engineered L1 element successfully copies itself into the genome. When SIRT1 was overexpressed, retrotransposition dropped sharply; when SIRT1 was knocked down with siRNA, retrotransposition rose. At the transcriptional level, L1 mRNA declined roughly 30 percent in cells overexpressing SIRT1, while CRISPR/Cas9-mediated knockout of SIRT1 increased L1 transcription, a pattern reproduced in IMR90 primary fibroblasts and mouse embryonic fibroblasts. Because L1 transcription is initiated by an internal promoter within its 5-prime untranslated region, the team tested that promoter directly using luciferase reporters. SIRT1 inhibited 5-prime UTR activity in a dose-dependent manner, and its absence boosted promoter activity approximately twofold, an effect fully reversed by reintroducing the protein.

To connect this transcriptional control to genome integrity, the researchers exploited the fact that L1’s ORF2 protein induces DNA strand breaks as part of the retrotransposition process. Using the alkaline comet assay, a single-cell method that detects strand breaks and converts other lesions into breaks under alkaline conditions, the team measured genomic instability through the tail moment, a quantitative descriptor of DNA damage. SIRT1 overexpression reduced the tail moment in a dose-dependent fashion, whereas SIRT1 deficiency exacerbated ORF2-induced genomic instability. Re-expression of wild-type SIRT1 rescued the phenotype. Consistent with these results, SIRT1 overexpression lowered the accumulation of gamma-H2AX, a canonical marker of DNA double-strand breaks, while SIRT1 knockdown raised it. In a striking twist, two catalytically inactive mutants of SIRT1, G261A and H363Y, suppressed L1 5-prime UTR activity and genomic instability just as effectively as the wild-type protein, demonstrating that the protective role operates independently of the enzyme’s NAD+-dependent deacetylase activity.

The team then asked what happens to cellular senescence when SIRT1 levels change. They induced senescence in HCA2-hTERT fibroblasts and HeLa cells using X-ray irradiation at doses of 10 and 8 Gy, then stained for senescence-associated beta-galactosidase seven to ten days later. SIRT1 overexpression cut the fraction of senescent cells nearly in half, from about 30 percent to 13 percent in HCA2-hTERT cells and from 38 percent to 20 percent in HeLa cells, while SIRT1 knockdown raised senescence by an additional 10 percent. Levels of the senescence markers p21 and p16 fell with SIRT1 overexpression and climbed with its depletion. The senescence-associated secretory phenotype, the inflammatory cocktail secreted by senescent cells, was likewise damped by SIRT1, as measured by the expression of factors such as CCL2, MMP3, IL-1 alpha, IL-1 beta, and IL-6. Because L1 is known to activate the cGAS-STING innate immune pathway, the researchers examined phosphorylation of TBK1 and STING, finding both reduced by SIRT1 overexpression and elevated by its knockdown. Notably, lamivudine, also known as 3TC, a nucleoside reverse transcriptase inhibitor that potently blocks L1, attenuated the senescence induced by SIRT1 deficiency, confirming L1 as the causal culprit.

A key insight emerged from the biology of quiescence. Prior work established that L1 retrotransposition requires cell division, and the new study suggests why: in quiescent cells, SIRT1 piles up at L1 loci. Chromatin immunoprecipitation in mouse skeletal muscle satellite cells revealed significantly increased SIRT1 enrichment at L1 elements under quiescent conditions. In cultured IMR90-SVLT cells made quiescent by contact inhibition, confirmed by reduced EdU incorporation and diminished Ki67 expression, endogenous SIRT1 bound the L1 5-prime UTR at levels far exceeding those seen in proliferating cells. Correspondingly, L1 transcript levels dropped in quiescent cells, indicating that the cell-cycle dependence of L1 retrotransposition stems in part from transcriptional repression by accumulated SIRT1.

To uncover how SIRT1 enforces this repression, the team performed immunoprecipitation with an anti-SIRT1 antibody followed by liquid chromatography-tandem mass spectrometry, comparing quiescent and proliferating cells. The screen identified a set of SIRT1-interacting proteins involved in heterochromatin organization, most prominently the nuclear lamin protein Lamin B1 and the corepressor KAP1, and these interactions proved specific to quiescent conditions. Reciprocal co-immunoprecipitation confirmed the SIRT1-Lamin B1 interaction in HEK293FT cells, and experiments with purified recombinant proteins demonstrated that the two bind directly. Physical interaction between SIRT1 and KAP1 had been validated previously. Crucially, SIRT1 did not change the protein levels of either partner; instead, it acted as a molecular matchmaker, enhancing the interaction between Lamin B1 and KAP1, a cooperativity that collapsed in SIRT1-knockout cells.

Chromatin immunoprecipitation assays then traced the functional consequences at L1 loci. In control cells, both Lamin B1 and KAP1 occupied specific regions of the L1 promoter, but this binding was abolished in SIRT1-knockout cells. Because KAP1 is known to recruit the histone methyltransferase SETDB1, heterochromatin protein 1, and the NuRD complex to shape H3K9me3, the characteristic epigenetic mark of constitutive heterochromatin, the team assessed that mark directly. Global H3K9me3 decreased upon SIRT1 knockdown, and H3K9me3 enrichment at L1 promoters dropped correspondingly. The picture that emerges is elegant: SIRT1 binds the L1 5-prime UTR, recruits Lamin B1 and KAP1, stabilizes their partnership, and thereby maintains the repressive H3K9me3 landscape that silences L1 transcription. This places SIRT1 in a mechanistic lineage shared with, yet distinct from, its sirtuin siblings SIRT6 and SIRT7, which also restrain L1 through heterochromatin pathways. SIRT6 ADP-ribosylates KAP1 to promote its association with HP1 alpha, while SIRT7 deacetylates H3K18 to tether L1 to lamin proteins. The family has clearly converged on transposon silencing through divergent molecular routes.

The authors acknowledge that their senescence models are limited to stress-induced, rather than replicative, senescence, and that many mechanistic experiments were performed in transformed or immortalized cell lines rather than primary cells, questions that future work must address under physiological conditions. Nevertheless, the study delivers a compelling new framework. As SIRT1 declines during aging, the heterochromatin architecture protecting L1 elements erodes, dormant retrotransposons awaken, cytoplasmic L1 nucleic acids trip the cGAS-STING alarm, and the senescence program accelerates. Interventions that preserve or restore SIRT1 function, or that pharmacologically block L1 reverse transcriptase with drugs like lamivudine, could theoretically break this vicious cycle. In linking a longevity enzyme, a genomic parasite, and an immune sensor of misplaced DNA, the research illuminates one of the molecular threads that binds retrotransposon derepression to the aging clock, and offers concrete targets for therapies designed to delay aging and mitigate age-related disease.

Subject of Research: The role of SIRT1 in silencing L1 retrotransposons through stabilization of heterochromatin-modifying complexes during cellular senescence.

Article Title: SIRT1 Silences L1 Retrotransposons by Stabilizing Heterochromatin‐Modifying Complexes

Article References: Wang, X., Li, T., Tang, H., Liu, M. X., Peng, Q., Huang, X., Mao, Z., Jiang, Y., & Geng, A. (2026). SIRT1 Silences L1 Retrotransposons by Stabilizing Heterochromatin‐Modifying Complexes. Aging Cell, 25(9), Article e70689. https://doi.org/10.1111/acel.70689

Image Credits: AI Generated

DOI: 10.1111/acel.70689

Keywords: SIRT1, L1 retrotransposon, cellular senescence, heterochromatin, H3K9me3, Lamin B1, KAP1, cGAS-STING, aging, Aging Cell, sirtuins, genomic instability

Neuronal senescence, a state traditionally associated with irreversible cell cycle arrest and the secretion of pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP), has long been investigated in dividing cells but remained elusive in postmitotic neurons until now. This study provides compelling evidence that DRG neurons exhibit senescence-like characteristics in response to the dual pressures of chronological aging and peripheral nerve trauma. The implications are far-reaching: the accumulation of senescent neurons is proposed as a key driver underlying the pathophysiology of age-related sensory deficits and the chronic pain syndromes frequently observed in elderly and injured populations.

Central to this mechanistic insight is the interplay between oxidative stress, DNA damage response pathways, and inflammatory signaling within DRG neurons. Aging is known to exacerbate cellular oxidative burden, causing persistent DNA lesions that evoke sustained activation of the p53/p21 axis, a canonical pathway mediating senescence. Furthermore, injury amplifies localized inflammatory cascades, resulting in microglial activation and the release of cytokines that further destabilize neuronal homeostasis. This compounded stress environment induces a phenotypic shift in DRG neurons that manifests as impaired ion channel regulation, altered electrophysiological properties, and amplified nociceptive sensitization.

Delving into molecular details, the study highlights the accumulation of γH2AX foci and increased expression of cyclin-dependent kinase inhibitors such as p16^INK4a and p21^WAF1/CIP1 in DRG neurons post-injury and with advancing age. These markers confirm a bona fide senescence signature previously thought incompatible with terminally differentiated neurons. The upregulation of SASP components including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMPs) reveals an active and deleterious neuron-driven pro-inflammatory state that may undermine the structural integrity of local neural networks and perpetuate nociceptive hypersensitivity.

Electrophysiological assessments corroborate these molecular findings by demonstrating reduced neuronal excitability and altered firing patterns in senescent DRG neurons. This functional decline mirrors the sensory deficits documented in aged populations, notably diminished tactile acuity and proprioception. Moreover, the persistent presence of SASP factors fosters an autocrine and paracrine milieu that recruits immune cells and aggravates neuroinflammation, establishing a vicious cycle that exacerbates neuronal dysfunction and inhibits regenerative potential.

Importantly, the research uncovers potential therapeutic avenues by exploring interventions that mitigate or reverse neuronal senescence within DRGs. Pharmacological agents targeting the senescence pathway, including senolytics that selectively eliminate senescent cells and senomorphics that suppress SASP secretion, show promise in restoring neuronal health and sensory function in experimental models. The therapeutic modulation of key signaling nodes such as p38 MAP kinase and NF-κB pathways, which regulate inflammatory SASP expression, also represents a strategic target to disrupt the feedback loop sustaining neuroinflammation and neuronal aging.

The methodologies employed in this research combine sophisticated in vivo animal models subject to controlled peripheral nerve injury with comprehensive transcriptomic profiling and high-resolution immunohistochemical analyses. Single-cell RNA sequencing permits the dissection of cellular heterogeneity within the DRG microenvironment, revealing distinct senescence subpopulations and their respective contributions to the overall pathology. These cutting-edge techniques offer a granular view of the sequential molecular events leading from injury to senescence, thus refining our mechanistic understanding and highlighting novel biomarkers for clinical assessment.

Of particular note is the implication that neuronal senescence may serve as a unifying pathological mechanism bridging aging and injury-related neurodegenerative processes. This hypothesis extends beyond sensory neurons, potentially illuminating similar pathways in other nervous system compartments implicated in diseases such as Alzheimer’s and Parkinson’s. The extrapolation of these findings could herald a paradigm shift in how age-associated neurodegeneration is conceptualized, paving the way for therapies targeting fundamental cellular aging processes rather than solely symptomatic treatment.

Beyond its clinical relevance, the study underscores the dynamic nature of neuronal aging and challenges the previously held dogma that postmitotic neurons are inert to classical senescence triggers. It reveals a plasticity in neuronal phenotype that can be maladaptively reprogrammed in response to environmental insults, thus broadening the conceptual framework for neuronal resilience and vulnerability. This nuanced perspective invites further exploration into how lifestyle factors, metabolic state, and systemic inflammation modulate the onset and progression of neuronal senescence in vivo.

Moreover, the findings raise critical questions about the intersection of peripheral nervous system aging and central nervous system function. The dorsal root ganglia serve as a critical relay point, and their deterioration likely impacts higher-order neural circuits governing complex sensory and motor functions. Understanding how local DRG senescence affects spinal cord and brain networks could inform multi-level therapeutic interventions designed to preserve or restore sensory system integrity across the lifespan.

This research also offers a timely lens into the considerable burden of chronic pain in aging societies. By elucidating the cellular underpinnings of pain sensitization post-injury amidst an aging backdrop, it provides a foundation for the development of targeted treatments designed not just to alleviate symptoms but to address root causative cellular dysfunction. This precision medicine approach holds promise for reducing reliance on opioids and other generalized analgesics, thereby mitigating side effects and improving quality of life for millions.

In summary, the emerging evidence that aging and injury synergistically drive neuronal senescence in dorsal root ganglia neurons constitutes a pivotal contribution to neuroscience and gerontology. It reframes our understanding of neuronal aging as an active, pathological process mediated by defined molecular pathways that are amenable to intervention. This landmark study lays the groundwork for translational strategies to combat sensory neuron decline and chronic pain through novel biochemical and genetic therapies targeting cellular senescence.

As research continues to unravel the complexities of neuronal aging and injury, the prospect of reversing or preventing neuronal senescence emerges as a transformative goal in medicine. The integration of senescence biology into neurorehabilitation and pain management paradigms could revolutionize care paradigms for the aging population. Ultimately, these insights ignite hope that the debilitating sensory consequences of aging and injury can be mitigated through innovative, targeted interventions, heralding a new era of neuro-restorative medicine.

—

Subject of Research: Neuronal senescence in dorsal root ganglia induced by aging and injury

Article Title: Aging and injury drive neuronal senescence in the dorsal root ganglia

Article References:
Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-01954-x

Image Credits: AI Generated